Over-the-Counter Medications That Elevate Post-Void Residual Urine Volume
The primary OTC medications that cause elevated post-void residual (PVR) urine volume are anticholinergic agents (including first-generation antihistamines like diphenhydramine and doxylamine), NSAIDs, and decongestants containing alpha-adrenergic agonists (such as pseudoephedrine and phenylephrine).
Anticholinergic Medications
Anticholinergic drugs are the most common OTC culprits for urinary retention. These medications impair detrusor muscle contractility by blocking muscarinic receptors in the bladder wall, directly preventing effective bladder emptying 1.
Common OTC anticholinergics include:
- First-generation antihistamines: Diphenhydramine (Benadryl), doxylamine (found in sleep aids like Unisom), chlorpheniramine, and hydroxyzine
- Sleep aids: Most OTC sleep medications contain diphenhydramine or doxylamine as active ingredients
- Motion sickness medications: Dimenhydrinate (Dramamine) and meclizine
The risk increases substantially with higher anticholinergic burden. Recent evidence demonstrates that an Anticholinergic Drug Score (ADS) ≥ 2 significantly increases the odds of urinary retention (OR 2.57,95% CI 1.06-6.28) 2. This means even moderate anticholinergic exposure from combining multiple OTC medications can precipitate retention.
NSAIDs
Non-steroidal anti-inflammatory drugs available OTC (ibuprofen, naproxen, aspirin) can cause urinary retention through prostaglandin inhibition, which affects detrusor contractility 1. While less commonly implicated than anticholinergics, NSAIDs pose particular risk when combined with other medications affecting bladder function.
Alpha-Adrenergic Agonists
OTC decongestants containing pseudoephedrine (Sudafed) or phenylephrine increase bladder outlet resistance by stimulating alpha-adrenergic receptors in the bladder neck and prostatic urethra 1. This mechanism is particularly problematic in men with underlying benign prostatic hyperplasia, even if previously asymptomatic.
High-Risk Populations
Elderly patients face exponentially higher risk due to:
- Pre-existing bladder outlet obstruction (benign prostatic hyperplasia in men)
- Age-related detrusor dysfunction
- Polypharmacy creating cumulative anticholinergic burden
- Baseline elevated PVR (older age independently predicts higher PVR) 2
The evidence shows that patients ≥75 years have a 3-fold increased risk of urinary retention (OR 3.02,95% CI 1.32-6.94) 2.
Critical Clinical Pitfalls
Avoid assuming "OTC equals safe": Up to 10% of urinary retention episodes are attributable to concomitant medication use 1. Many patients don't report OTC medications unless specifically asked.
Watch for medication combinations: The cumulative effect of multiple agents with mild anticholinergic properties (e.g., antihistamine + NSAID + decongestant for cold symptoms) can precipitate acute retention even when individual agents might be tolerated alone.
Gender differences matter: Men have higher baseline PVR than women and are more susceptible to retention from alpha-agonists due to prostatic effects 3.
Management Approach
When elevated PVR is detected, systematically review all OTC medications. Discontinue or reduce the dose of the causal agent immediately, particularly anticholinergics and decongestants 1. If acute retention occurs, catheterization may be necessary while the offending medication is cleared.
For patients requiring ongoing symptom management (e.g., allergies, pain), recommend alternatives with lower anticholinergic burden: second-generation antihistamines (loratadine, cetirizine, fexofenadine) have minimal anticholinergic effects and are safer choices for patients at risk of urinary retention.